CRISPR Therapeutics AG (CRSP) Non-Current Deffered Revenue (2015 - 2025)

CRISPR Therapeutics AG (CRSP) has 11 years of Non-Current Deffered Revenue data on file, last reported at $12.3 million in Q3 2025.

• For the quarter ending Q3 2025, Non-Current Deffered Revenue changed 0.0% year-over-year to $12.3 million; the trailing twelve-month figure through Sep 2025 stood at $12.3 million (changed 0.0% YoY), and the FY2024 full-year result was $12.3 million, down 12.05% from the prior year.
• Non-Current Deffered Revenue steadied at $12.3 million in Q3 2025, from $12.3 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $15.8 million in Q3 2023 to a low of $11.8 million in Q2 2021.
• A 5-year average of $12.6 million and a median of $12.3 million in 2021 frame the typical range for Non-Current Deffered Revenue.
• Across the five-year window, Non-Current Deffered Revenue rose 28.4% in 2023 and retreated 22.12% in 2024, its largest moves.
• Tracing CRSP's Non-Current Deffered Revenue over 5 years: stood at $12.3 million in 2021, then changed by 0.0% to $12.3 million in 2022, then advanced by 13.71% to $14.0 million in 2023, then fell by 12.05% to $12.3 million in 2024, then changed by 0.0% to $12.3 million in 2025.
• Business Quant data shows CRSP's Non-Current Deffered Revenue at $12.3 million in Q3 2025, $12.3 million in Q2 2025, and $12.3 million in Q1 2025.